Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liver Cancer Clear all
Terminated Phase 1 Interventional

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

NCT02323906
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CC-122, Sorafenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

NCT02435433
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Ramucirumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

NCT00083785
View directory record Official record
Conditions
Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
Interventions
Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED), Photodynamic therapy, Phototherapy, Chemotherapy
Drug · Device · Procedure
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2007 · Synced Sep 17, 2026, 1:48 AM EDT
Recruiting Phase 1 Interventional

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

NCT02174549
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
Interventions
Tirapazamine, Conventional Transarterial Embolization (TAE)
Drug · Procedure
Lead sponsor
Teclison Ltd.
Industry
Eligibility
20 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
2
States / cities
Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

NCT00012155
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
NV1020
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 17, 2026, 1:48 AM EDT
Recruiting No phase listed Observational

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

NCT01416714
View directory record Official record
Conditions
Gastric Cancers
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor

NCT00706576
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Infusion of opioid growth factor
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 17, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

NCT04965714
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma
Interventions
Nivolumab, Pegargiminase, Resection
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 3 Interventional

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

NCT00825955
View directory record Official record
Conditions
Liver Cancer
Interventions
Brivanib, Placebo, Best Supportive Care
Drug · Other · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
19
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

NCT00055692
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

NCT00554372
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Genetic
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

Defining the Ablative Dose for Y-90 TARE

NCT07586046
View directory record Official record
Conditions
HCC - Hepatocellular Carcinoma
Interventions
Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Not applicable Interventional

Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer

NCT00003186
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
isosulfan blue, lymphangiography, sentinel lymph node biopsy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer

NCT02015754
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DEBIRI, LC Bead M1, TACE
Drug · Device · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 17, 2026, 1:48 AM EDT
Recruiting No phase listed Observational

Molecular Basis of Pediatric Liver Cancer

NCT03959800
View directory record Official record
Conditions
Childhood Liver Cancer, Liver Malignant Tumors, Embryonal Sarcoma of Liver (Disorder), Hepatoblastoma, Hepatocellular Carcinoma, Rhabdoid Tumor of Liver
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
0 Years to 99 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Active, not recruiting Not applicable Interventional

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions
Resin microspheres containing yttrium-90 (Y-90)
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction

NCT00037804
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor
Interventions
Irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Detroit, Michigan • New Brunswick, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Sep 17, 2026, 1:48 AM EDT
Terminated Phase 1 Interventional

Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors

NCT00955097
View directory record Official record
Conditions
Liver Tumors
Interventions
Definity®
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction

NCT00005077
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Sep 17, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for Lung Cancer Chemoprevention

NCT00780234
View directory record Official record
Conditions
Lung Cancer, Endobronchial Dysplasia
Interventions
fluorescence bronchoscopy, quantitative high resolution CT scan, PIOGLITAZONE VS. PLACEBO 30 mg
Procedure · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 17, 2026, 1:48 AM EDT